German Biotech's $6.4M Seed Round Targets Heart Disease's Hidden Biology

Jan de Vries · 2026-08-28

There's a quiet but significant launch happening in Heidelberg. Revier Therapeutics, a new European biotech startup, has just come out of stealth with a mission to tackle some of the most stubborn cardiometabolic diseases. And they're doing it with a fresh $6.4 million in seed funding to back their novel approach. That's right, about $6.4 million USD, converted from the €6 million round announced. It's a solid start for a company aiming to rewrite the treatment playbook for conditions affecting millions. The funding was spearheaded by the KHAN Technology Transfer Fund II. They weren't alone—High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors through Revier Invest Heidelberg all joined in. It’s a coalition that sees the potential in Revier's science. This kind of regional support is a hallmark of Europe's deep-tech ecosystem, where investors often bet on foundational research with long-term horizons. ### The Unmet Need Driving Innovation So, what's the big deal here? Prof. Eva van Rooij, PhD, the company's CEO and co-founder, puts it plainly. She says that despite all our advances, millions of patients with specific heart conditions are still stuck with limited options. We're talking about heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). These aren't rare issues; they're massive burdens on global health. "The next generation of medicines has to go deeper," van Rooij suggests. "It's not just about managing symptoms. We need to address the underlying biology that's driving the disease in the first place. That's the only way to create solutions that are both impactful and lasting for patients." ### A First-of-its-Kind Therapeutic Strategy Here's where Revier's story gets interesting. They're going after a target called class IIa histone deacetylases, or HDACs. In simple terms, these are enzymes that play a role in how genes are expressed, and when they go awry, they can contribute to severe diseases. Previous HDAC inhibitors were a bit like using a sledgehammer—they hit multiple classes of HDACs, which often led to nasty side effects that limited how much medicine a patient could tolerate. Revier is trying to be a scalpel. Their orally available small molecules are designed to be selective. They aim to inhibit only the specific, disease-causing activity of class IIa HDACs while leaving their healthy functions—and other critical enzymes—alone. Prof. Johannes Backs, MD, the scientific founder, breaks it down. "Our first-in-class molecules are built for precision," he says. "This targeted mode of action is what we believe will lead to a therapy that's both effective and has a much better safety profile." ### Why Investors Are Betting on This Approach The investor confidence isn't just about the science; it's about the team and the strategy's potential to sidestep past failures. Michael Hamacher, PhD, of KHAN Technology Transfer Fund II, highlighted the combination of deep scientific expertise and a leadership team that knows how to translate research into medicine. He pointed out that Revier's strategy could "unlock the therapeutic promise of HDAC biology" that earlier, less selective approaches couldn't reach. The goal is nothing less than reshaping the standard of care for these chronic disorders. ### What's Next for the Capital? With the seed capital secured, the path forward is clear. The money will fuel: - Advancing their preclinical pipeline, with a lead program focused on HFpEF. - Developing a second program targeting ASCVD. - Building out the company's operational, scientific, and clinical teams to prepare for the journey toward human trials. It’s a classic biotech story: take groundbreaking academic research, assemble a world-class team, secure smart capital, and aim for a clinical breakthrough. For professionals watching the European startup and life sciences scene, Revier Therapeutics is a name to remember. They represent the kind of deep, targeted innovation that could eventually translate into meaningful new options for patients waiting for better answers.